JPWO2020081613A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020081613A5 JPWO2020081613A5 JP2021520915A JP2021520915A JPWO2020081613A5 JP WO2020081613 A5 JPWO2020081613 A5 JP WO2020081613A5 JP 2021520915 A JP2021520915 A JP 2021520915A JP 2021520915 A JP2021520915 A JP 2021520915A JP WO2020081613 A5 JPWO2020081613 A5 JP WO2020081613A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- sequence
- guide
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 312
- 229920002391 Guide RNA Polymers 0.000 claims description 274
- 108020005004 Guide RNA Proteins 0.000 claims description 274
- 210000004027 cells Anatomy 0.000 claims description 273
- 125000003729 nucleotide group Chemical group 0.000 claims description 62
- 150000007523 nucleic acids Chemical class 0.000 claims description 61
- 239000002773 nucleotide Substances 0.000 claims description 57
- 101700083255 TRBC1 Proteins 0.000 claims description 47
- 102100009727 TRBC1 Human genes 0.000 claims description 47
- 239000011230 binding agent Substances 0.000 claims description 46
- 230000004568 DNA-binding Effects 0.000 claims description 40
- 108020004707 nucleic acids Proteins 0.000 claims description 33
- 108091008153 T cell receptors Proteins 0.000 claims description 24
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 24
- 230000014509 gene expression Effects 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 9
- 108091008191 immune receptors Proteins 0.000 claims description 9
- 102000025599 immune receptors Human genes 0.000 claims description 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000038129 antigens Human genes 0.000 claims description 8
- 108091007172 antigens Proteins 0.000 claims description 8
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 6
- 108010082319 CRISPR-Associated Protein 9 Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000008383 Wilms Tumor Diseases 0.000 claims description 4
- 229920000033 CRISPR Polymers 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 2
- 238000000520 microinjection Methods 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 description 38
- 101700070835 NCOR2 Proteins 0.000 description 36
- 102100001100 TRAC Human genes 0.000 description 36
- 101700078141 TRAC Proteins 0.000 description 36
- 102100009726 TRBC2 Human genes 0.000 description 32
- 101700003299 TRBC2 Proteins 0.000 description 32
- 229920001184 polypeptide Polymers 0.000 description 19
- 238000009472 formulation Methods 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000004048 modification Effects 0.000 description 7
- 238000006011 modification reaction Methods 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 6
- 230000003612 virological Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000000295 complement Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000735 allogeneic Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 241000432074 Adeno-associated virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746522P | 2018-10-16 | 2018-10-16 | |
| US62/746,522 | 2018-10-16 | ||
| US201862747037P | 2018-10-17 | 2018-10-17 | |
| US62/747,037 | 2018-10-17 | ||
| PCT/US2019/056399 WO2020081613A1 (en) | 2018-10-16 | 2019-10-15 | Compositions and methods for immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512703A JP2022512703A (ja) | 2022-02-07 |
| JPWO2020081613A5 true JPWO2020081613A5 (ru) | 2022-10-24 |
Family
ID=68502008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520915A Pending JP2022512703A (ja) | 2018-10-16 | 2019-10-15 | 免疫療法のための組成物および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210340530A1 (ru) |
| EP (1) | EP3867379A1 (ru) |
| JP (1) | JP2022512703A (ru) |
| KR (1) | KR20210091160A (ru) |
| CN (1) | CN113227374A (ru) |
| AU (1) | AU2019362879A1 (ru) |
| BR (1) | BR112021007025A2 (ru) |
| CA (1) | CA3116132A1 (ru) |
| CO (1) | CO2021006301A2 (ru) |
| IL (1) | IL282225A (ru) |
| MX (1) | MX2021004214A (ru) |
| PH (1) | PH12021550849A1 (ru) |
| SG (1) | SG11202103571XA (ru) |
| TW (1) | TW202035693A (ru) |
| WO (1) | WO2020081613A1 (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4237560A1 (en) * | 2020-10-30 | 2023-09-06 | Arbor Biotechnologies, Inc. | Compositions comprising an rna guide targeting trac and uses thereof |
| TW202235617A (zh) | 2020-12-11 | 2022-09-16 | 美商英特利亞醫療公司 | 用於減少細胞中ii類mhc之組合物及方法 |
| CR20230320A (es) | 2020-12-23 | 2023-10-23 | Intellia Therapeutics Inc | Composiciones y métodos para reducir los hla-a en una célula |
| MX2023007465A (es) | 2020-12-23 | 2023-08-18 | Intellia Therapeutics Inc | Composiciones y metodos para modificar geneticamente ciita en una celula. |
| AU2021411521A1 (en) | 2020-12-30 | 2023-08-03 | Intellia Therapeutics, Inc. | Engineered t cells |
| WO2022170193A2 (en) | 2021-02-08 | 2022-08-11 | Intellia Therapeutics, Inc. | T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy |
| WO2022170172A1 (en) | 2021-02-08 | 2022-08-11 | Intellia Therapeutics, Inc. | Natural killer cell receptor 2b4 compositions and methods for immunotherapy |
| JP2024505678A (ja) | 2021-02-08 | 2024-02-07 | インテリア セラピューティクス，インコーポレイテッド | 免疫療法のためのリンパ球活性化遺伝子３（ｌａｇ３）組成物及び方法 |
| WO2022206941A1 (zh) * | 2021-04-02 | 2022-10-06 | 克莱格医学有限公司 | Cs1工程化细胞及其组合物 |
| WO2023028471A1 (en) | 2021-08-24 | 2023-03-02 | Intellia Therapeutics, Inc. | Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy |
| WO2023081200A2 (en) | 2021-11-03 | 2023-05-11 | Intellia Therapeutics, Inc. | Cd38 compositions and methods for immunotherapy |
| WO2023148494A1 (en) * | 2022-02-03 | 2023-08-10 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| WO2023205148A1 (en) | 2022-04-19 | 2023-10-26 | Intellia Therapeutics, Inc. | Chimeric antigen receptor compositions and uses |
| WO2023225670A2 (en) * | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| TW202409271A (zh) | 2022-06-16 | 2024-03-01 | 美商英特利亞醫療公司 | 用於減少細胞中之ｍｈｃ １類之組成物及方法 |
| WO2024006955A1 (en) | 2022-06-29 | 2024-01-04 | Intellia Therapeutics, Inc. | Engineered t cells |
| WO2024088401A1 (en) * | 2022-10-28 | 2024-05-02 | CorrectSequence Therapeutics Co., Ltd | Gene editing systems and methods for reducing immunogenicity and graft versus host response |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| ATE515510T1 (de) | 1991-12-24 | 2011-07-15 | Isis Pharmaceuticals Inc | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide |
| US6169169B1 (en) | 1994-05-19 | 2001-01-02 | Dako A/S | PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| US8993233B2 (en) | 2012-12-12 | 2015-03-31 | The Broad Institute Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| EP3553174A1 (en) | 2012-12-17 | 2019-10-16 | President and Fellows of Harvard College | Rna-guided human genome engineering |
| EA030650B1 (ru) | 2013-03-08 | 2018-09-28 | Новартис Аг | Липиды и липидные композиции для доставки активных агентов |
| US9937207B2 (en) * | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
| WO2014191128A1 (en) * | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| US20170175128A1 (en) * | 2014-04-18 | 2017-06-22 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| US20150376587A1 (en) | 2014-06-25 | 2015-12-31 | Caribou Biosciences, Inc. | RNA Modification to Engineer Cas9 Activity |
| WO2016022400A1 (en) | 2014-08-04 | 2016-02-11 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
| AU2015339744B2 (en) * | 2014-10-31 | 2021-03-25 | The Trustees Of The University Of Pennsylvania | Altering gene expression in CART cells and uses thereof |
| CA2978314A1 (en) | 2015-03-03 | 2016-09-09 | The General Hospital Corporation | Engineered crispr-cas9 nucleases with altered pam specificity |
| US20180112213A1 (en) * | 2015-03-25 | 2018-04-26 | Editas Medicine, Inc. | Crispr/cas-related methods, compositions and components |
| BR112017020750A2 (pt) * | 2015-03-27 | 2018-06-26 | Harvard College | células t modificadas e métodos de produção e utilização das mesmas |
| EP3277294B1 (en) * | 2015-04-01 | 2024-05-15 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
| MX2018006767A (es) * | 2015-12-04 | 2019-03-14 | Novartis Ag | Composiciones y metodos para oncologia inmunologica. |
| WO2017112944A1 (en) * | 2015-12-23 | 2017-06-29 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
| WO2017136794A1 (en) | 2016-02-03 | 2017-08-10 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
| CA3016331A1 (en) * | 2016-03-04 | 2017-09-08 | Editas Medicine, Inc. | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy |
| TWI773666B (zh) | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
| CN110291198A (zh) | 2016-12-08 | 2019-09-27 | 因特利亚治疗公司 | 经修饰的指导rna |
| US20210137978A1 (en) * | 2017-01-10 | 2021-05-13 | The General Hospital Corporation | Modified t cells and methods of their use |
| WO2018191490A1 (en) * | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
| CA3081320A1 (en) * | 2017-10-30 | 2019-05-09 | Pact Pharma, Inc. | Primary cell gene editing |
| CN109750035B (zh) * | 2017-11-02 | 2020-06-05 | 上海邦耀生物科技有限公司 | 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA |
| CN107746831B (zh) * | 2017-11-07 | 2019-04-23 | 南京北恒生物科技有限公司 | 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法 |
-
2019
- 2019-10-15 BR BR112021007025-7A patent/BR112021007025A2/pt unknown
- 2019-10-15 JP JP2021520915A patent/JP2022512703A/ja active Pending
- 2019-10-15 MX MX2021004214A patent/MX2021004214A/es unknown
- 2019-10-15 WO PCT/US2019/056399 patent/WO2020081613A1/en active Application Filing
- 2019-10-15 KR KR1020217014333A patent/KR20210091160A/ko unknown
- 2019-10-15 AU AU2019362879A patent/AU2019362879A1/en active Pending
- 2019-10-15 SG SG11202103571XA patent/SG11202103571XA/en unknown
- 2019-10-15 CN CN201980082863.9A patent/CN113227374A/zh active Pending
- 2019-10-15 CA CA3116132A patent/CA3116132A1/en active Pending
- 2019-10-15 EP EP19801126.4A patent/EP3867379A1/en active Pending
- 2019-10-16 TW TW108137354A patent/TW202035693A/zh unknown
-
2021
- 2021-04-11 IL IL282225A patent/IL282225A/en unknown
- 2021-04-15 US US17/231,556 patent/US20210340530A1/en active Pending
- 2021-04-15 PH PH12021550849A patent/PH12021550849A1/en unknown
- 2021-05-13 CO CONC2021/0006301A patent/CO2021006301A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200299661A1 (en) | Cpf1-related methods and compositions for gene editing | |
| JPWO2020081613A5 (ru) | ||
| US11186825B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1 | |
| EP3368689B1 (en) | Composition for modulating immune responses by use of immune cell gene signature | |
| US11180730B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3 | |
| US20170349914A1 (en) | DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF CRISPR SYSTEMS AND COMPOSITIONS FOR GENOME EDITING AS TO HEMATOPOIETIC STEM CELLS (HSCs) | |
| US20190262399A1 (en) | Compositions and methods for evaluating and modulating immune responses | |
| KR20160097327A (ko) | 유전자 산물, 구조 정보 및 유도성 모듈형 ｃａｓ 효소의 발현의 변경을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 방법 | |
| KR20160097331A (ko) | 뉴클레오티드 반복 장애에서의 ｃｒｉｓｐｒ-ｃａｓ 시스템의 조성물 및 방법 및 용도 | |
| JP7479399B2 (ja) | 癌腫瘍に対するテーラード低免疫ナノ小胞送達系 | |
| Bank | Human somatic cell gene therapy | |
| KR20230053591A (ko) | 조작된 근육 표적화 조성물 | |
| JP2018534114A5 (ru) | ||
| JP2022547570A (ja) | 操作済みのアデノ随伴ウイルスキャプシド | |
| CA3100262A1 (en) | Compositions and methods for haematopoietic stem cell transplantation | |
| WO2022261115A1 (en) | Peptide nucleic acids for spatiotemporal control of crispr-cas binding | |
| Sii-Felice et al. | Innovative therapies for hemoglobin disorders | |
| US20220010274A1 (en) | Personalized neoantigen-specific adoptive cell therapies | |
| CN117716026A (zh) | 具有氧化应激抗性的间充质干细胞、其制备方法及用途 | |
| IL299491A (en) | Methods and compositions for B2M LOCUS editing in B cells | |
| Harrison et al. | Current challenges of gene therapy for prostate cancer | |
| KR20200129959A (ko) | 무-운반체 다중 CRISPR/Cas 9 유전자 편집 복합체 및 그의 용도 | |
| US20110213006A1 (en) | Compositions and Methods for Treatment of Uncontrolled Cell Growth | |
| CN114072518B (zh) | 用于治疗地中海贫血或镰状细胞病的方法和组合物 | |
| JP2010521460A (ja) | 癌免疫療法におけるＩｉ−ＲＮＡｉ関与Ｉｉ抑制 |